Eurestobart | m-entrepreneurship.com

Product Name :
Eurestobart

Search keywords :
CD39

drugId :
null

Target Vo:
Ectonucleoside triphosphate diphosphohydrolase 1

Target Vo Short Name :
CD39

Moa_Name:
Anti-Ectonucleoside triphosphate diphosphohydrolase 1

First Approval Country :

First Approval Date Filter:
null

Origin Company_Name :
Elpiscience (Shanghai) Biopharma Ltd

Active Company_Name :
Elpiscience Biopharma Ltd

Active Indication_Name:
Solid tumours

In Active Indication_Name:

Termination Status :

China Termination Status :

Highest Status:
Phase 1 Clinical

China Highest Status:
Phase 1 Clinical

Antibodies are immunoglobulins secreted by effector lymphoid B cells into the bloodstream. Antibodies consist of two light peptide chains and two heavy peptide chains that are linked to each other by disulfide bonds to form a “Y” shaped structure. Both tips of the “Y” structure contain binding sites for a specific antigen. Antibodies are commonly used in medical research, pharmacological research, laboratory research, and health and epidemiological research. They play an important role in hot research areas such as targeted drug development, in vitro diagnostic assays, characterization of signaling pathways, detection of protein expression levels, and identification of candidate biomarkers.
Related websites: https://www.medchemexpress.com/antibodies.html
Popular product recommendations:
Cytochrome C Antibody
PKR Antibody
RANKL/CD254 Antibody: RANKL/CD254 Antibody is an unconjugated, approximately 35 kDa, rabbit-derived, anti-RANKL/CD254 polyclonal antibody. RANKL/CD254 Antibody can be used for: WB, ELISA, IHC-P, IHC-F, Flow-Cyt, IF expriments in human, mouse, and predicted: rat, dog background without labeling.

Author: Betaine hydrochloride

Related Posts